• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Oragenics Inc. Common Stock (NY:OGEN)

    0.8996 -0.0604 (-6.29%)
    Streaming Delayed Price Updated: 11:34 AM EDT, Mar 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 279,204
    Open 0.9900
    Bid (Size) 0.8802 (600)
    Ask (Size) 0.8994 (500)
    Prev. Close 0.9600
    Today's Range 0.8700 - 0.9900
    52wk Range 0.6111 - 9.600
    Shares Outstanding 4,168,223
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Initiates First Clinical Site for Phase IIa Trial of ONP-002 in Australia
    Via Investor Brand Network
    BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Explores CNS Asset Acquisitions To Expand Brain Health Pipeline
    Via Investor Brand Network

    Performance

    YTD
    +7.7%
    +7.7%
    1 Month
    +25.3%
    +25.3%
    3 Month
    -3.3%
    -3.3%
    6 Month
    -21.8%
    -21.8%
    1 Year
    -89.5%
    -89.5%

    More News

    Read More
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Receives Australian Ethics Approval to Launch Phase IIa Concussion Trial
    Via Investor Brand Network
    BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Previews 2026 Milestones for Intranasal Concussion Therapeutic ONP-002
    Via Investor Brand Network
    BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Engages DUCK FLATS Pharma for IND Readiness and Regulatory Execution
    Via Investor Brand Network
    BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Participates in SCOPE Summit 2026 Ahead of Phase 2a Concussion Trial
    Via Investor Brand Network
    BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) to Present at Sequire Investor Summit 2026
    Via Investor Brand Network
    BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Regains NYSE Compliance, Advances Toward First Clinical Trial and Expands AI-Driven Neurology Pipeline
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Oragenics Q3 2025 Shareholder Update
    From Oragenics, Inc.
    Via Business Wire
    BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Regains NYSE Compliance, Strengthens Balance Sheet for Clinical Advancement
    Via Investor Brand Network
    News headline image
    Oragenics Regains Full NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
    From Oragenics, Inc.
    Via Business Wire
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Partners with Receptor.AI to Accelerate AI-Driven Discovery of Brain-Targeted Therapeutics
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development
    From Oragenics
    Via Business Wire
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Highlights Q2 2025 Progress and Prepares for Phase IIa Concussion Trial
    Via Investor Brand Network
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Selects Southern Star Research as CRO for Phase IIa Trial of Intranasal Concussion Therapy ONP-002
    Via Investor Brand Network
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Secures U.S. Manufacturing Partner Ahead of Phase IIb Trials for Concussion Drug
    Via Investor Brand Network
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
    Via Benzinga
    News headline image
    Monday's after hours session: top gainers and losers ↗
    Via Chartmill
    InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Secures $16.5 Million in Preferred Stock Offering to Advance Intranasal Concussion Therapy
    Via Investor Brand Network
    News headline image
    Get insights into the top gainers and losers of Wednesday's after-hours session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
    Via Benzinga
    News headline image
    What's going on in today's after hours session ↗
    Via Chartmill
    News headline image
    Which stocks are moving on Tuesday? ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Nasdaq Dips 150 Points; US ISM Manufacturing PMI Rises In June ↗
    Via Benzinga

    Frequently Asked Questions

    Is Oragenics Inc. Common Stock publicly traded?
    Yes, Oragenics Inc. Common Stock is publicly traded.
    What exchange does Oragenics Inc. Common Stock trade on?
    Oragenics Inc. Common Stock trades on the New York Stock Exchange
    What is the ticker symbol for Oragenics Inc. Common Stock?
    The ticker symbol for Oragenics Inc. Common Stock is OGEN on the New York Stock Exchange
    What is the current price of Oragenics Inc. Common Stock?
    The current price of Oragenics Inc. Common Stock is 0.8996
    When was Oragenics Inc. Common Stock last traded?
    The last trade of Oragenics Inc. Common Stock was at 03/13/26 11:34 AM ET
    What is the market capitalization of Oragenics Inc. Common Stock?
    The market capitalization of Oragenics Inc. Common Stock is 3.75M
    How many shares of Oragenics Inc. Common Stock are outstanding?
    Oragenics Inc. Common Stock has 4M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.